Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1480027
This article is part of the Research Topic Interplay of Epigenetic Regulation and Cellular Metabolism in Cancer Microenvironments View all 6 articles

RIPK1 in necroptosis and recent progress in related pharmaceutics RIPK1 in necroptosis and pharmaceutics

Provisionally accepted
Kunhou Yao Kunhou Yao 1*Zhihao Shi Zhihao Shi 2Fengya Zhao Fengya Zhao 2*Tan Cong Tan Cong 2Yixin Zhang Yixin Zhang 2*Hao Fan Hao Fan 2Yingzhe Wang Yingzhe Wang 2*Xingwang Li Xingwang Li 1Jun Kong Jun Kong 2*Qun Wang Qun Wang 2*Dingxi Li Dingxi Li 3*
  • 1 Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan Province, China
  • 2 Henan University, Kaifeng, China
  • 3 Department of Gynaecology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

The final, formatted version of the article will be published soon.

    Necroptosis is a programmed form of cell death. Receptor-interacting serine/threonine protein kinase l (RIPK1) is a crucial protein kinase that regulates the necroptosis pathway.increases the susceptibility of cells to apoptosis and necroptosis. RIPK1, RIPK3, and mixedlineage kinase-like domain (MLKL) proteins mediate necrosis. RIPK1-mediated necroptosis further promotes cell death and inflammation in the pathogenesis of liver injury, skin diseases, and neurodegenerative diseases. The N-terminal kinase domain of RIPK1 is significant in the 2 induction of cell death and can be used as a vital drug target for inhibitors. In this paper, we outline the pathways of necroptosis and the role RIPK1 plays in them and suggest that targeting RIPK1 in therapy may help to inhibit multiple cell death pathways.

    Keywords: ripk1, necroptosis, programmed cell death, Inflammation, Kinase domain, Pharmaceutics

    Received: 22 Aug 2024; Accepted: 10 Jan 2025.

    Copyright: © 2025 Yao, Shi, Zhao, Cong, Zhang, Fan, Wang, Li, Kong, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Kunhou Yao, Department of General Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan Province, China
    Fengya Zhao, Henan University, Kaifeng, China
    Yixin Zhang, Henan University, Kaifeng, China
    Yingzhe Wang, Henan University, Kaifeng, China
    Jun Kong, Henan University, Kaifeng, China
    Qun Wang, Henan University, Kaifeng, China
    Dingxi Li, Department of Gynaecology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.